EXOSENS RAISES FULL-YEAR 2026 GUIDANCE, DRIVEN BY FASTER-THAN-EXPECTED CAPACITY RAMP-UP AND STRONG COMMERCIAL MOMENTUM

  • Faster-than-expected ramp-up of additional European production capacity for high-performance image intensifier tubes, meeting growing global demand for advanced night vision solutions sooner than anticipated
  • Accelerating adoption of mission-critical imaging technologies across drone, counter-drone and long-range surveillance applications
  • Strong momentum in nuclear instrumentation, driven by increasing demand for next-generation SMR technologies
  • 2026 guidance raised: c.20% revenue growth and c.25% adjusted EBITDA growth at midpoint vs. 2025, implying further profitability improvement
    • Revenue in the range of €558-570 million (vs. €520-540 million previously)
    • Adjusted EBITDA in the range of €186-192 million (vs. €168-178 million previously)

Press release, Mérignac (France), 17 September 2026 – Exosens (EXENS; FR001400Q9V2), a high-tech company focused on providing mission- and performance-critical amplification, detection and imaging technologies, today announces an upward revision to its full-year 2026 guidance.

This guidance upgrade builds on Exosens’ strong first-half 2026 performance and reflects sustained commercial momentum and continued disciplined execution driving industry-leading profitability.

In Amplification, Exosens maintained production throughout August at its European facilities for the first time, with the extended operating schedule implemented as planned. Newly installed production equipment was also successfully commissioned. These operational milestones have confirmed the faster-than-expected ramp-up of additional capacity for high-performance image intensifier tubes in Europe, enabling the Group to meet growing global demand for advanced night vision solutions sooner than anticipated.

In Detection & Imaging, Exosens continues to benefit from the accelerating adoption of its mission-critical imaging technologies across drone, counter-drone and long-range surveillance applications. To meet this growing customer demand, the Group is scaling its industrial capabilities, with plans to triple production capacity for thermal cameras and double capacity for cooled infrared cameras in 2026. Commercial momentum in nuclear instrumentation also remains strong, particularly in next-generation SMR applications.

Against this backdrop, Exosens is raising its full-year 2026 guidance and now expects:

  • Revenue in the range of €558 million to €570 million (compared with €520 million to €540 million previously);
  • Adjusted EBITDA in the range of €186 million to €192 million (compared with €168 million to €178 million previously);
  • Capital expenditure at around 9% of revenue (excluding capitalized R&D expenses of around 3% of revenue), driven by production capacity expansion in Europe and the U.S. (unchanged).

“Building on our strong first-half performance, we continue to see sustained commercial momentum across our markets. The faster-than-expected ramp-up of additional European production capacity for high-performance image intensifier tubes enables us to meet growing global demand for advanced night vision solutions sooner than anticipated. At the same time, our imaging technologies continue to gain traction, particularly across drone and surveillance applications, while demand in the nuclear market remains strong. This sustained momentum, combined with continued operational discipline, gives us confidence to raise our full-year 2026 guidance and supports our industry-leading profitability. Firmly focused on executing our strategy, we are well positioned to leverage our expanding industrial capabilities and recognized technology leadership to capture additional commercial opportunities and deliver sustained profitable growth over the long term,” said Jérôme Cerisier, CEO of Exosens.

Exosens will communicate its full-year 2027 guidance upon publication of the Group’s full-year 2026 results on 22 February 2027.

Financial calendar

  • 27/10/2026: 9M 2026 revenue and adjusted gross margin (before market opening).
  • 22/02/2027: FY 2026 results (before market opening).

About Exosens

Exosens is a high‐tech company, with more than 85 years of experience in the innovation, development, manufacturing and sale of high‐end electro‐optical technologies in the field of amplification, detection and imaging. Today, it offers its customers detection components and solutions such as advanced cameras, neutron and gamma detectors, instrument detectors and light intensifier tubes. This allows Exosens to respond to complex issues in extremely demanding environments by offering tailor-made solutions to its customers. Thanks to its sustained investments, Exosens is internationally recognized as a major innovator in optoelectronics, with production and R&D carried out on 13 sites, in Europe and North America, and with over 2,000 employees. Exosens is listed on compartment A of Euronext Paris regulated market (Ticker: EXENS; ISIN: FR001400Q9V2). Exosens is a member of Euronext Tech Leaders segment and is also included in several indices, including SBF 120, CAC All-Tradable, CAC Mid 60, FTSE Total Cap and MSCI France Small Cap. For more information: www.exosens.com.

Investor Relations

Laurent Sfaxi, l.sfaxi@exosens.com

Media Relations

Brunswick Group, exosens@brunswickgroup.com

Forward-looking statements

Certain information included in this press release is not historical fact but constitutes forward-looking statements. These forward-looking statements are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future business strategies and the environment in which Exosens operates, and involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed in or implied by the forward-looking statements included in this press release. These risks and uncertainties include those set out and detailed in Chapter 4 “Risk factors and risk management system” of the Universal Registration Document filed on 9 March 2026 with the French financial markets authority (Autorité des marchés financiers – AMF) under number D.26-0072. Forward-looking statements speak only as of the date of this press release, and the Group expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements included in this press release to reflect any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Group. Actual results could differ materially from those expressed in, or implied or projected by, forward-looking information and statements. This press release is provided for information purposes only. It does not constitute, and should not be deemed to constitute, an offer to the public of securities.

Attachment

LA HULPE, BELGIUM – 17 September 2026, 7:00 a.m. CEST – Banqup Group SA (Euronext: BANQ) (Banqup, Company), a European fintech provider that simplifies financial flows through an innovative secured platform for e-invoicing, e-payment, e-reporting and e-trust solutions with built-in compliance at its core, today announced an operational and growth update on its footprint in the French market, timed with the 81st Congress of the Expert-Comptable Media Association (ECMA). Following years of regulatory delays across France, the official launch of the national e-invoicing mandate has triggered a significant growth in the number of users, proving the long-term strategic value of Banqup’s partner-led expansion model.

Partner-led blueprint delivers unprecedented scale

Banqup serves as the core technology provider behind jefacture.com, the accredited platform (Plateforme Agréée / PA) created by ECMA—the digital arm established by the French National Board of Chartered Accountants (CNOEC).

Rather than building costly direct sales networks, Banqup leveraged ECMA’s trusted distribution channel to embed its financial operating platform directly into the accounting ecosystem. Today, this channel strategy accounts for:

  • Almost 175,000 registered business clients, actively using the platform.
  • Nearly 4,900 chartered accounting firms, directing their client networks onto jefacture.com.

This partner-led Go-To-Market (GTM) playbook serves as the primary template Banqup is replicating across other key European growth markets facing mandatory e-invoicing transitions. Also, the onboarded network is an opportunity for upsell towards other products such as the payment module.

Management Commentary

“We have consistently communicated to our shareholders that the French market represented a major growth driver for Banqup,” said Koen De Brabander, CEO of Banqup Group. “While regulatory postponements delayed the initial timeline, the current adoption metrics prove that our patience and strategic execution is paying off. jefacture.com is now operating as a primary engine of automated financial workflows in France, validating our technology stack and our ability to monetize complex compliance shifts.”

Contact

David Geleyn
Head of Investor Relations – Banqup Group
investor.relations@banqup.com
media@banqup.com 

About ECMA & jefacture.com

Being a non-profit organisation created by the French National Council of the Order of Chartered Accountants, ECMA provides digital solutions simplifying and securing daily business of chartered accountants. ECMA supports French chartered accountants and their clients to their constant digital transformation. Among these solutions, jefacture.com is the e-invoicing platform designed by chartered accountants for their clients. jefacture.com is used on a daily basis by thousands of accounting firms and SMEs.

About Banqup Group

Banqup Group (Euronext Brussels: BANQ) architects the trust infrastructure needed to thrive in a digital-first economy. As a specialized European fintech provider and licensed payment institution, Banqup revolutionizes buying and selling for businesses and governments worldwide by digitalising financial supply chain processes within a secure, tax-compliant business network.

Moving beyond traditional software, Banqup operates a unified, open network platform that links business actors, accounting networks, banks, ERP systems, and tax authorities. Built around four interconnected pillars—e-invoicing, e-payments, e-reporting, and e-trust—Banqup enables digitisation of end-to-end order-to-cash and procure-to-pay workflows in full compliance with different regulatory frameworks.

Headquartered in Belgium with a history of pioneering digital transformation since 2001, Banqup is powering growth through effortless financial flows.

To learn more, visit www.banqup.com.

Cautionary note regarding forward-looking statements: The statements contained herein may include prospects, statements of future expectations, opinions, and other forward-looking statements in relation to the expected future performance of Banqup Group and the markets in which it is active. Such forward-looking statements are based on management’s current views and assumptions regarding future events. By nature, they involve known and unknown risks, uncertainties, and other factors that appear justified at the time at which they are made but may not turn out to be accurate. Actual results, performance or events may, therefore, differ materially from those expressed or implied in such forward-looking statements. Except as required by applicable law, Banqup Group does not undertake any obligation to update, clarify or correct any forward-looking statements contained in this press release in light of new information, future events or otherwise and disclaims any liability in respect hereto. The reader is cautioned not to place undue reliance on forward-looking statements.

Attachment

Wereldhave N.V. (‘Wereldhave’), through Wereldhave Belgium (70% owned by Wereldhave), announces the sale of retail park De Mael in Bruges (Belgium) to a consortium of private investors. The divestment of this non-core asset is in line with Wereldhave’s strategy to reduce leverage while focusing its portfolio on Full Service Centers.

Gross proceeds from the transaction amount to € 49.2 million, excluding transfer tax, reflecting a premium to the asset’s latest book value. Proceeds from the sale will further strengthen Wereldhave’s balance sheet, reducing the net loan-to-value (LTV) ratio by approximately 110bps compared with 30 June 2026. Transfer of the asset is scheduled for Q2 2027.

“This divestment reflects our disciplined approach to portfolio management. While our recent acquisitions in Belgium and Luxembourg have been made at net initial yields of 8%+, we have now sold De Mael at a 5.6% net initial yield. This accretive capital rotation strengthens our balance sheet while sharpening our focus on Full Service Centers.” said Matthijs Storm, CEO of Wereldhave.

Wereldhave was advised on the transaction by Avenue Real Estate.

About retail park De Mael
De Mael is a modern retail park in Bruges, Belgium, comprising approximately 20,000 m² GLA with excellent accessibility and a strong regional catchment area. Acquired by Wereldhave in 2018, the asset has undergone a comprehensive transformation programme into a future-proof retail destination anchored by a strong mix of retailers, including Albert Heijn XL, Dreamland, MediaMarkt, Brico, HEMA, Pearle, TUI and Medi-Market.

Attachment

  • Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment
  • Data reinforce the potential of this Lunsumio-based regimen to improve clinical outcomes, while offering a tolerable safety profile, simple dosing schedule and outpatient administration
  • Data will be submitted to health authorities and presented at an upcoming medical meeting

Basel, 17 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab) in combination with lenalidomide versus MabThera®/Rituxan® (rituximab) plus lenalidomide in people with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one prior line of treatment met its primary endpoint. Results demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS). Overall survival (OS) data were immature at the time of interim analysis. The safety profile of the Lunsumio and lenalidomide combination was consistent with the known profiles of the individual study medicines, with no new safety signals identified. Data from the study will be submitted to health authorities and presented at an upcoming medical meeting.

“People living with relapsed or refractory follicular lymphoma need treatment options that provide meaningful clinical benefit and minimal disruptions to everyday care,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development.  “The CELESTIMO results indicate that a two-drug outpatient Lunsumio regimen may offer these patients an effective new option earlier in their treatment journey.”

CELESTIMO is a confirmatory study required to convert the accelerated approval/conditional marketing authorisation of Lunsumio monotherapy for third-line or later (3L+) FL to full approval, as well as to secure an indication in second-line or later (2L+) FL.

Lunsumio is part of Roche’s industry-leading CD20xCD3 bispecific antibody programme. It is designed with the unique needs and preferences of patients in mind, offering the possibility of outpatient treatment and flexibility between intravenous and subcutaneous administration routes. Lunsumio is already approved for people with 3L+ FL in 60 countries worldwide and has been used to treat over 3,800 patients.1

With the longest follow-up data of any bispecific antibody in lymphoma and a broad clinical development programme spanning multiple disease settings, including both FL and diffuse large B-cell lymphoma (DLBCL), Lunsumio is helping redefine care across B-cell malignancies. The U.S. Food and Drug Administration (FDA) recently accepted the supplemental Biologics License Application (sBLA) for Lunsumio in combination with Polivy® (polatuzumab vedotin) for 2L+ DLBCL based on the SUNMO study, and results from CELESTIMO support continued expansion of Lunsumio and lenalidomide into earlier FL treatment, with the phase III MorningLyte study ongoing in first-line FL.

About the CELESTIMO study
CELESTIMO [NCT04712097] is a phase III trial evaluating the efficacy and safety of Lunsumio® (mosunetuzumab) in combination with lenalidomide vs. MabThera®/Rituxan® (rituximab) plus lenalidomide in people with relapsed or refractory follicular lymphoma (FL) who have received at least one line of prior systemic therapy. It is a confirmatory study required to convert the accelerated approval/conditional marketing authorisation of Lunsumio monotherapy for third-line or later FL to full approval, as well as to secure an indication in second-line or later FL.

About follicular lymphoma
Follicular lymphoma (FL) is the most common slow-growing (indolent) form of non-Hodgkin lymphoma, accounting for about one in five cases.2 It typically responds well to treatment but is often characterised by periods of remission and relapse.3 The disease typically becomes harder to treat each time a patient relapses, and early progression can be associated with poor long-term prognosis.4 It is estimated that more than 110,000 people are diagnosed with FL each year worldwide.5

About Lunsumio® (mosunetuzumab)
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate malignant B cells. Lunsumio is currently approved as a fixed-duration monotherapy for the treatment of adult patients with third-line or later relapsed or refractory follicular lymphoma (FL) in both intravenous and subcutaneous (Lunsumio VELO™) formulations. A robust, global development programme is ongoing to explore the clinical utility of Lunsumio earlier in the disease course and in novel combinations, including the phase III CELESTIMO trial in second-line or later FL.

About Roche in haematology
Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), Polivy® (polatuzumab vedotin), Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibody cevostamab, targeting both FcRH5 and CD3. Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Roche data on file.
[2] Lymphoma Research Foundation. About Follicular Lymphoma. [Internet; cited September 2026]. Available from: https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/follicular-lymphoma/
[3] Lymphoma Action. Follicular Lymphoma. [Internet; cited September 2026]. Available from: https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/follicular-lymphoma
[4] Skarbnik AZ et al. Treatment selection for patients with relapsed or refractory follicular lymphoma. Front Oncol. 2023;13:1120358.
[5] World Health Organization. Numbers derived from GLOBOCAN 2022. Non-Hodgkin Lymphoma Factsheet [Internet; cited September 2026]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf.

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz
Phone: +41 79 529 70 35
Lorena Corfas
Phone: +41 79 568 24 95

 

Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83

 

Kirti Pandey
Phone: +41 79 398 38 53
Yvette Petillon
Phone: +41 79 961 92 50

 

Irène Stephan
Phone:  +41 79 377 83 75
Albert Thottiyil
Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

 

Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
 

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

 

Attachment

Vancouver, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on humanoid robotics and embodied AI, notes the launch of AutomationFinder.com.au by Robotics Australia Group (“RAG”), Australia’s national peak body for robotics, automation and physical AI. The platform is powered by HowToRobot, a Humanoid Global portfolio company.

Humanoid Global holds a minority equity interest in HowToRobot through its US$75,000 participation in HowToRobot’s Series A financing, announced on February 26, 2026. Humanoid Global also serves on HowToRobot’s advisory board pursuant to a two-year advisory agreement under which it provides strategic advice to HowToRobot for no monetary compensation. Humanoid Global does not control or operate HowToRobot and is not a party to the arrangement between HowToRobot and RAG.

RAG launched AutomationFinder.com.au on September 1, 2026 as a vendor-neutral platform intended to help Australian businesses identify automation opportunities, prepare supplier-ready project briefs, assess feasibility and cost, compare potential solutions and connect with automation providers.

According to RAG, the platform draws on more than 600 real automation projects and combines HowToRobot’s technology and methodology, including its global network of more than 20,000 automation suppliers, of which up to 500 are in Australia, with RAG’s industry knowledge, relationships and local reach. RAG has described the partnership as HowToRobot’s first country-wide licensed deployment.

“We believe a national licence is a meaningful step for HowToRobot,” said Sunny Ray, Chief Executive Officer of Humanoid Global. “Helping a business work out what is worth automating, and who can deliver it, is often the hardest part of adoption. We’re glad to support the HowToRobot team as an investor and advisor.”

-##-

About Humanoid Global Holdings Corp.

Humanoid Global Holdings Corp. (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF) (“Humanoid Global” or the “Company”) is a publicly traded investment issuer building a portfolio of pioneering companies in the growing humanoid robotics and embodied AI sector, investing in and accelerating their growth. It serves as a global investment platform providing liquidity and access to an actively managed portfolio spanning the value chain of this emerging ecosystem, including advanced software, hardware, and enabling technologies. Led by a team with a proven track record of scaling transformative technologies globally, the Company takes a long-term, partnership-oriented approach. It provides capital and strategic consultation on go-to-market strategies, regulatory pathways, and transaction advisory, while facilitating introductions to customers, suppliers, and strategic partners.

Learn more: https://www.humanoidglobal.ai/

For further information, please contact:

Sunny Ray
Chief Executive Officer
finance@humanoidglobal.ai
info@humanoidglobal.ai
(604) 602-0001

CSE:ROBO
OTCQB:RBOHF
FWB:0XM1

ON BEHALF OF MANAGEMENT

Sunny Ray
Chief Executive Officer

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding: the anticipated adoption, use, development and expansion of AutomationFinder.com.au; the anticipated benefits and functionality of the platform; HowToRobot’s ability to support and expand its licensing model, supplier network and international operations; the anticipated demand for automation planning, sourcing and related services; and the Company’s expectations regarding its investment in and advisory relationship with HowToRobot.

Forward-looking information is based on assumptions that HowToRobot and RAG will continue to operate and support AutomationFinder.com.au substantially as described; that the relationship between HowToRobot and RAG will continue; that market demand for automation-related services will develop as anticipated; and that HowToRobot will have sufficient capital, personnel, technology, suppliers and commercial partners to pursue its business objectives. These assumptions may prove to be incorrect.

The Company holds a minority equity interest in HowToRobot and serves on its advisory board, and therefore has a financial interest in HowToRobot’s success. Readers should consider this interest when evaluating the information in this news release.

Forward-looking information is subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including: the risk that AutomationFinder.com.au may not achieve anticipated user, supplier or commercial adoption; the risk that the platform may not deliver anticipated functionality, benefits or market acceptance; the risk that the relationship between HowToRobot and RAG may be modified, suspended or terminated; risks relating to HowToRobot’s ability to scale its licensing model, platform, supplier network and international operations; technology, cybersecurity, data security and intellectual property risks; the risk that automation projects may not proceed or achieve anticipated benefits; competition; regulatory changes; general economic and market conditions; and risks relating to the Company’s reliance on portfolio companies in which it holds minority interests and over which it has no control.

Additional risks are described in the Company’s public filings available under its profile on SEDAR+ at www.sedarplus.ca. Forward-looking information speaks only as of the date of this news release, and the Company undertakes no obligation to update or revise it except as required by applicable law. Readers are cautioned not to place undue reliance on forward-looking information.

Certain information regarding HowToRobot, RAG and AutomationFinder.com.au has been derived from RAG’s September 1, 2026 public announcement and other publicly available materials. Humanoid Global has not independently verified this information. The Company is not the operating company and is not a party to the licensing arrangement, customer relationships or other operating activities described in this news release, and nothing in this news release should be read as suggesting that the Company itself has entered into or achieved any such arrangement.

Wereldhave Belgium sells De Mael retail park in Sint-Kruis (Bruges) and strengthens its financial position

PRESS RELEASE | Vilvoorde, 17 September 2026

Wereldhave Belgium has reached a conditional private sale agreement with a consortium of private investors for the sale of De Mael retail park in Sint-Kruis, Bruges. The transaction is in line with the company’s strategic focus on dominant mid-sized shopping centers in Belgium and Luxembourg.

The selling price amounts to €49.2 million, excluding transfer tax, exceeding the asset’s latest book value. The transaction reflects a net initial yield of 5.6%. The transfer of the asset is expected to take place in the second quarter of 2027 and has no impact on the previously communicated outlook for the 2026 financial year.

Since its acquisition in 2018, De Mael has undergone an extensive transformation, including renovations, investments in sustainability and mobility, and a strengthened tenant mix. Through the sale, Wereldhave Belgium realises the value built up at the site and strengthens its financial position to support further growth and pursue new investment opportunities.

More from Wereldhave Belgium | Latest news

The full press release is available as an attachment.

Attachment

Not for distribution to U.S. Newswire Services or for dissemination in the United States.

TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — Real Estate Split Corp. (TSX: RS and RS.PR.A) (the “Company”), announces that it has filed an Amended and Restated Prospectus Supplement relating to its previously announced overnight treasury offering of class A and preferred shares (the “Class A Shares” and “Preferred Shares”, respectively). The Amended and Restated Prospectus Supplement incorporates DBRS’s September 15, 2026 update to the Preferred Shares’ rating to Pfd-3.

The offering prices remain unchanged at $9.15 per Class A share and $10.45 per preferred share. Gross Proceeds of the Offering are expected to be $21.5 million and the Offering is expected to close on or about Wednesday, September 23, 2026, subject to certain closing conditions, including approval by the Toronto Stock Exchange.

The syndicate of agents for the offering was co-led by CIBC Capital Markets, RBC Capital Markets, and Scotiabank, and included National Bank Financial Inc., Canaccord Genuity Corp., Hampton Securities Limited, BMO Nesbitt Burns Inc., CI Investor Services Inc., iA Private Wealth Inc., Raymond James Ltd., Manulife Wealth Inc., Ventum Financial Corp., Wellington-Altus Private Wealth Inc., Desjardins Securities Inc., and Research Capital Corporation.

For further information, please visit our website at www.middlefield.com or contact our Sales and Marketing Department at 1.888.890.1868.

A short form base shelf prospectus containing important detailed information about the securities being offered has been filed with securities commissions or similar authorities in each of the provinces and territories of Canada. Copies of the short form base shelf prospectus may be obtained from a member of the syndicate. The Company intends to file a supplement to the short form base shelf prospectus, and investors should read the short form base shelf prospectus and the prospectus supplement before making an investment decision. There will not be any sale or any acceptance of an offer to buy the securities being offered until the prospectus supplement has been filed with the securities commissions or similar authorities in each of the provinces and territories of Canada.

Atos partners with GCH to open new AI-Driven Security Operations Center in the UAE

Omar Beydoun, General Manager UAE, Atos; Hemalsinh Gohil, Director Sales, Middle East & Africa, Gulf Cyberfender Hub; Surendrasinh Gohil, CEO, Gulf Cyberfender Hub (GCH); Mohammed Himmath, Chief Information Officer, Gulf Data Hub; Ghassan Muheisen, Client Delivery Manager, Atos; Daniele Principato, EVP & Head of International Markets, Atos; Amit Roy, Global Head of Growth, Cyber, Atos.
Omar Beydoun, General Manager UAE, Atos; Hemalsinh Gohil, Director Sales, Middle East & Africa, Gulf Cyberfender Hub; Surendrasinh Gohil, CEO, Gulf Cyberfender Hub (GCH); Mohammed Himmath, Chief Information Officer, Gulf Data Hub; Ghassan Muheisen, Client Delivery Manager, Atos; Daniele Principato, EVP & Head of International Markets, Atos; Amit Roy, Global Head of Growth, Cyber, Atos.

Atos partners with GCH to open new AI-Driven Security Operations Center in the UAE

Next Gen Dubai-based SOC supports local data residency, national cyber resilience priorities and faster response to regional and AI- threats

Dubai, United Arab Emirates – September 17, 2026 – Atos, a global leader of AI-powered digital transformation, today announced the opening of its new AI-driven Security Operations Center (SOC) in the United Arab Emirates in partnership with GCH. The new Dubai-based SOC will provide sovereign security operations with local data residency, helping organizations strengthen cyber resilience, address regional and AI-driven threats, and support compliance with UAE Information Assurance Standards and National Electronic Security Authority requirements.

The opening supports the UAE’s national cyber resilience priorities by providing locally operated monitoring, detection and incident response capabilities. The SOC is designed to help government entities, critical infrastructure operators and enterprises, retain greater control over security data and operations within the UAE, while strengthening governance and alignment with local regulatory requirements.

The SOC will use advanced analytics, automation and AI-driven operations to accelerate threat detection, investigation and response. Using Agentic AI to significantly reduce Mean Time to Detect (MTTD) and Mean Time to Respond (MTTR), Atos aims to help customers reduce cyber risk and strengthen overall business resilience as threat actors increasingly use AI to automate and scale attacks.

The UAE SOC will collaborate with the Atos Global Threat Research Center to provide curated threat intelligence informed by global visibility and tailored to the local and regional threat landscape. This approach combines Atos’ international cyber expertise with locally relevant intelligence to support faster and more informed security decisions.

Daniele Principato, head of International Markets, Atos, said: “We are proud to bring AI-powered security operations to the UAE, combining local control with global intelligence in an increasingly complex and fast-evolving threat landscape. Together with GCH, we enable customers to respond faster, safeguard critical operations, and advance their digital sovereignty.”

Surendrasinh Gohil, CEO, Gulf Cyberfender Hub (GCH), said : “The launch a joint UAE Security Operations Center reflects our shared commitment with Atos to supporting the UAE’s vision for digital sovereignty and cyber resilience. By bringing together Atos’ global cybersecurity expertise and GCH’s regional capabilities, we are enabling organizations to benefit from locally hosted, AI-powered security operations that deliver faster threat detection, rapid incident response and enhanced protection against emerging cyber threats.”

Designed to defend against both conventional and AI-driven attacks, the SOC will combine human expertise with AI-enabled detection, investigation and response. Its local operating model and connection to Atos’ global threat research capabilities as well as the Atos Global SOC network will support organizations across the UAE and the wider region as they modernize their security operations and build more resilient digital environments.

***

About Atos

Atos is the Atos Group brand dedicated to AI-powered, secure, end-to-end digital services. Atos designs, develops, and operates critical digital environments that drive performance, resilience and sovereignty, helping public and private organizations worldwide retain control over their data and infrastructures, while meeting regulatory requirements.

With more than 52,000 employees serving over 4,500 clients across 54 countries, Atos helps modernize core IT systems, accelerate cloud and data transformation, strengthen cybersecurity, and deliver secure digital workplace environments to support its clients, its employees and society. Atos also provides consulting and advisory services through its Atos Amplify brand.

A trusted partner in operating complex and mission-critical environments, Atos supports organizations across highly regulated and sovereign contexts.

About Atos Group

Atos Group is a global leader in digital transformation with c. 54,000 employees and annual revenue of c. €7.2 billion, operating in 54 countries under two brands – Atos for services and Eviden for products and systems. European number one in cybersecurity and a leader in cloud, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos Group is listed on Euronext Paris.

About Gulf Cyberfender Hub (GCH)

Gulf Cyberfender Hub (GCH) is a technology consulting and digital solutions company headquartered in Dubai, UAE. GCH is helping enterprises to innovate, automate, optimize and protect their business in the area of Infrastructure Management, Application Management and Cybersecurity. GCH guides enterprises’ digital security architecture during their digital transformation and helps customers understand the cyber security landscape, create a cyber security roadmap that aligns with IT strategy and business goals, and ensure maximum return on their Information Technology Investment. 

Press contact

Lucie.leonardi@atos.ai

Attachments

DUBAI, United Arab Emirates, Sept. 16, 2026 (GLOBE NEWSWIRE) — FREELANDER, the British Premium Intelligent All-Terrain Brand, today announced the appointment of Al Tayer Motors and Premier Motors as its authorised distributors in the UAE, marking an important milestone in the brand’s international expansion. Lucia Mao, CEO of FREELANDER International, joined Matar Humaid Al Tayer, Vice-Chairman, Al Tayer Group, Saeed Humaid Al Tayer, Managing Director and Ashok Khanna, CEO, representing Al Tayer Motors and Premier Motors, to formalise the partnerships.

Image 1_Group Photo

Matar Humaid Al Tayer, Vice-Chairman, Al Tayer Group, Saeed Humaid Al Tayer, Managing Director and Ashok Khanna, Chief Executive Officer, Mona Hasan Sadoun, VP – Customer Experience & Marketing, representing Al Tayer Motors and Premier Motors with Lucia Mao, Chief Executive Officer, FREELANDER International and Andrew Ding, Country Director, FREELANDER, at the signing.

As FREELANDER’s first international market, the UAE will play a strategic role in the brand’s entry into the Middle East. Preparations are underway for the upcoming Global Brand Launch, officially set for 29 September in Abu Dhabi.

Al Tayer Motors has been appointed as FREELANDER’s authorised distributor across Dubai and the Northern Emirates. The brand will also be represented by Premier Motors in Abu Dhabi. With more than 40 years of experience representing top-tier automotive brands, Al Tayer Motors and Premier Motors bring established premium-segment expertise and a comprehensive sales, service and parts network to the partnership.

“FREELANDER represents an exciting addition to our portfolio. Our deep knowledge of the local market and experience in the premium automotive sector will support the brand’s growth in the UAE,” said Saeed Humaid Al Tayer, Managing Director of Al Tayer Motors and Premier Motors. “We are committed to bringing new mobility solutions to our UAE customers.”

Together, the two distributors operate a network of 32 sales and service facilities in the UAE, with capabilities spanning vehicle logistics, parts supply, warranty management, after-sales and award-winning customer service in-store and online. As part of the launch plan, three flagship showrooms have been secured in Dubai and Abu Dhabi.

Lucia Mao, CEO of FREELANDER International, commented: “These appointments mark a significant milestone in FREELANDER’s Middle East strategy. We are confident that our partnership with these two reputable distributors will give powerful impetus to the global roll-out of FREELANDER 8.”

Image 2_FREELANDER 8

As the brand’s first strategic model, FREELANDER 8 is built on the brand’s three core product pillars — British Craftsmanship, Smart Confidence and All-Terrain Freedom. Representing the next chapter of Legend Reborn, it brings premium design, intelligent technologies and all-terrain capability together for Freedom Seekers. With its UAE distribution network taking shape, FREELANDER is set to host its Global Brand Launch in Abu Dhabi on 29 September, kicking off the next phase of its international expansion.

About FREELANDER
FREELANDER is a British Premium Intelligent All-Terrain brand co-created by Chery and Jaguar Land Rover. JLR leads the design and premium DNA, while Chery brings advanced technology and global top-tier supply chain capabilities. The brand is supported by a strong global foundation, including over 5,000 employees, five strategic hubs, and fully integrated capabilities spanning design, R&D, manufacturing, and global operations.

Vincent CHEN
freelander.international@mychery.com
https://www.cheryinternational.com/

Photos accompanying this announcement are available at: 
https://www.globenewswire.com/NewsRoom/AttachmentNg/04bf22e6-8276-4bbd-8668-9ef877333077
https://www.globenewswire.com/NewsRoom/AttachmentNg/36d4652e-7446-44aa-89ea-44eafae6cb7c

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.